Academic
Publications
Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting

Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting,10.1136/bjo.2009.170670,Briti

Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting   (Citations: 5)
BibTex | RIS | RefWorks Download
BackgroundTo analyse the 24-month outcomes of intravitreal ranibizumab injections for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).MethodsThe authors reviewed the charts of all consecutive eyes with CNV secondary to AMD, who underwent one intravitreal ranibizumab injection (followed by a pro re nata (1+PRN) decision to retreat or to not retreat) at least 24 months before. Best-corrected visual acuity (BCVA) changes and central macular thickness (CMT) were retrospectively assessed, from baseline (m0) to month 12 (m12), and 24 (m24).ResultsNinety-six eyes of 79 patients (23 male, 56 female, aged 63–90 years) were included for analysis. The number of intravitreal injections administered ranged from 1 to 16. The mean BCVA significantly improved from m0 (0.78±0.33) to m12 (0.61±0.39, p<0.001), and m24 (0.65±0.38, p<0.001). The mean CMT significantly decreased from m0 (323.7±118.1) to m12 (254.6±92.3, p<0.001), and m24 (259.0±89.9, p<0.001). At m24, subretinal fluid, cystoid macular oedema and pigment epithelium detachment were present in fewer eyes (13, 31 and 31 eyes respectively), compared with m0 (33, 61 and 72 eyes, respectively). Overall, at m12 and m24, 91 eyes (94.8%) and 84 eyes (87.5%) lost fewer than 15 letters, and 25 (26%) eyes and 24 eyes (25%) improved by 15 letters or more, respectively; five eyes (5.2%) and 12 eyes (12.5%) lost more than 15 letters, at m12 and m24, respectively.ConclusionIn this study, similarly to other studies of variable dosing regimen over 24 months, intravitreal ranibizumab was effective in significantly increasing BCVA and reducing CMT.
Journal: British Journal of Ophthalmology - BRIT J OPHTHALMOL , vol. 94, no. 3, pp. 292-296, 2009
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...The SUSTAIN study evaluated the outcome of three loading doses of ranibizumab followed by as-needed OCT-guided dosing regimen on 531 patients with NV-AMD. Similarly, our results also mirror the outcomes of the lucentis monotherapy arm of the Verteporfin Photodynamic Therapy Administered in Conjunction with Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation Secondary to AMD (MONT BLANC) study that showed a mean gain of 4.4 letters with a mean injection rate of 5.1 at end of 12 months. Our study mirrors the results of the SUSTAIN and MONT BLANC studies and demonstrates that a PRN dosing schedule with a mean of five injections annually will only result in a gain of approximately one ETDRS line of vision in real-life settings....

    Bhaskar Guptaet al. Comparison of two intravitreal ranibizumab treatment schedules for neo...

    • ...showed that monthly visits, for both functional and morphological monitoring, are necessary in patients undergoing intravitreal anti-vascular endothelial growth factor (VEGF) treatment for AMD in order to take optimal re-treatment decisions....

    Giuseppe Querqueset al. Preferential hyperacuity perimeter in assessing responsiveness to rani...

    • ...However, despite the overall trend of losing some of the gained visual acuity, some reports have shown relatively good outcomes of the variable dosing regimen [8, 22, 23]...

    Alessandro Marianiet al. Characteristics of eyes with secondary loss of visual acuity receiving...

Sort by: